Outcomes in COVID-19 ensitrelvir studies
0
0.5
1
1.5+
All studies 45% 1
28
Improvement, Studies, Patients Relative Risk Viral clearance 45% 1
28
RCTs 45% 1
28
Early 45% 1
28
Ensitrelvir for COVID-19 c19early.com/en Oct 2022
Favors ensitrelvir Favors control
0
0.5
1
1.5+
ALL STUDIES
VIRAL CLEARANCE
RCTS
All
Early
Ensitrelvir for COVID-19
C19EARLY.COM/EN OCT 2022
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Early treatment 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement All studies 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement 1 ensitrelvir COVID-19 study c19early.com/en Oct 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Effect extraction pre-specified (most serious outcome) Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Early treatment 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement All studies 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement 1 ensitrelvir COVID-19 viral clearance result c19early.com/en Oct 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Early treatment 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement All studies 45%
0.55 [0.37-0.81]
0/14
0/14
45% improvement 1 ensitrelvir COVID-19 Randomized Controlled Trials c19early.com/en Oct 2022
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0025
Effect extraction pre-specified (most serious outcome) Favors ensitrelvir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mukae (DB RCT) 45%
0.55 [0.37-0.81]
viral load
14 (n)
14 (n)
Improvement, RR [CI] Treatment Control Mukae (DB RCT) 36%
0.64 [0.41-1.00]
viral load
15 (n)
14 (n)
Mukae (DB RCT) 45%
0.55 [0.34-0.90]
viral time
15 (n)
14 (n)
Mukae (DB RCT) 44%
0.56 [0.35-0.92]
viral time
13 (n)
14 (n)
Mukae (DB RCT) 54%
0.46 [0.05-4.38]
viral+
1/12
2/11
Mukae (DB RCT) -10%
1.10 [0.22-5.51]
viral+
3/15
2/11
Mukae (DB RCT) 80%
0.20 [0.01-3.80]
viral+
0/13
2/13
Mukae (DB RCT) 54%
0.46 [0.05-4.53]
viral+
1/14
2/13
Mukae (DB RCT) 54%
0.46 [0.10-2.12]
viral+
2/14
4/13
Mukae (DB RCT) 90%
0.10 [0.01-1.77]
viral+
0/15
4/13
Mukae (DB RCT) 80%
0.20 [0.05-0.75]
viral+
2/14
10/14
Mukae (DB RCT) 63%
0.37 [0.15-0.92]
viral+
4/15
10/14
Mukae (DB RCT) 9%
0.91 [0.59-1.40]
viral+
10/14
11/14
Mukae (DB RCT) -10%
1.10 [0.79-1.55]
viral+
13/15
11/14
ensitrelvir COVID-19 outcomes c19early.com/en Oct 2022
Favors ensitrelvir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
